Tag: Kempen
The Netherlands Market Review, December 2019: the return of ING
Europe | Market Reviews
08 Jan 2020 by Marc Wolterink
Fourteen structured products struck in The Netherlands in December. There were also 1,699 leverage products added while 153 products matured during the month.
Van Lanschot targets investors in Belgium with Dutch success story
Europe | Products
16 Dec 2019 by Marc Wolterink
The Dutch private bank returns to the Belgian market after a five-year absence with a product that proofed highly popular with investors in The Netherlands.
Product wrap: Milleis, BNP Paribas offer access to Euronext ESG index via life-insurance contract
International | Products
15 Nov 2019 by Marc Wolterink
This week’s wrap covers a selection of structured products with strike dates between November 10-16 2019.
The Netherlands Market Review - June 2019
Europe | Market Reviews
30 Jul 2019 by Marc Wolterink
Fifty-eight structured products struck in the Netherlands in June. There were also 1,217 leverage products added while 133 products matured during the month.
The Netherlands Market Review - April 2019
Europe | Market Reviews
31 May 2019 by Marc Wolterink
Four tranche structured products struck in the Netherlands in April. There were also 14 flow certificates and 1,035 leverage products. Eleven products matured during the month.
The Netherlands Market Review - February 2019
Europe | Market Reviews
31 Mar 2019 by Marc Wolterink
Eleven structured products were added to the SRP Netherlands database in February. There were also 537 turbos and three products matured.
Financial, societal returns can go hand in hand, research finds
International | Industry
26 Mar 2019 by Marc Wolterink
There is growing demand among investors to contribute to better world as research shows one-fifth of listed companies globally make positive impact
Van Lanschot Kempen FY2018: lower gains on structured products
Europe | Industry
28 Feb 2019 by Marc Wolterink
The oldest independent institution in the Netherlands has collected more than €4 million in commissions on structured products despite lower issuance levels
